Ustekinumab was conceived and employed starting from 2009 for the treatment of psoriasis, specifically for the inhibition of the drivers of Th1/Tc1 and Th17/Tc17 responses, with consequent reductions in IFN-γ- and IL-17-dependent systemic and cutaneous inflammation [2]. This evidence concerns the gene IL17A and psoriasis.